Abstract
Introduction
In 2006, the unstable angina/non-ST-elevation myocardial infarction
(UA/NSTEMI) market, valued at more than $820 million in the United States,
Europe, and Japan, was dominated by a handful of premium-priced therapies,
including Schering-Plough' s gpIIb/IIIa inhibitor Integrilin and
Sanofi-Aventis' low-molecular weight heparin Lovenox. Nine existing drug
classes and complicated treatment regimens make for a crowded and competitive
market; nonetheless, huge unmet clinical need provides an attractive
commercial opportunity for new treatments that demonstrate efficacy and safety
superior to that of currently available treatments. Several new agents are set
to enter the market before 2011, including Eli Lilly' s ADP receptor antagonist
prasugrel, GlaxoSmithKline' s Factor Xa inhibitor Arixtra, Schering-Plough' s
thrombin receptor antagonist SCH-530348, and The Medicines Company' s
cangrelor. The launch of these drugs will impact currently available therapies
and contribute to revenue growth, driving the UA/NSTEMI market to more than $1
billion in 2011.
Questions Answered in This Report
- Schering-Plough dominated the UA/NSTEMI market in 2006, with a market
share in excess of 40%, almost double that of the next leading competitor.
How has Schering-Plough secured such a dominant market share? What
strategies will the company employ to sustain a leading position over the
forecast period?
- Cardiologists and interventional cardiologists have been cautious in their
uptake of expensive new agents because of the need for cost containment and
the lack of perceived improvement over existing agents. What do physicians
identify as the key attributes of currently marketed agents? What are the
perceived advantages and/or disadvantages of emerging therapies versus
available therapies?
- Plavix is currently the gold standard for antiplatelet therapy; however,
Eli Lilly' s highly anticipated prasugrel and The Medicines Company' s cangrelor
have the potential to radically change the ADP receptor antagonist drug class
dynamic. Other agents in development also have the potential to compete
directly with Plavix. What products are being developed in the major
competitors' pipelines? How will emerging drugs perform if approved for
UA/NSTEMI treatment?
- UA/NSTEMI is part of a broader set of cardiovascular conditions that
includes acute coronary syndrome (ACS) and thrombosis-related disorders, and
it is distinct from primary care cardiovascular conditions such as
dyslipidemia and hypertension. How does UA/NSTEMI fit into the wider
cardiovascular therapeutic area? What strategies are being pursued to achieve
success in this treatment area?
Scope
- Markets Covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
- Competitive Analysis: Detailed discussion of major competitors,
including Schering-Plough, Sanofi-Aventis, Bristol-Myers Squibb, Eli Lilly,
Merck, and The Medicines Company, as well as the emerging competitor
GlaxoSmithKline. Included is an analysis of each company' s cardiovascular
product portfolio, strategic positioning, and development pipeline in
UA/NSTEMI. The report features an in-depth discussion of leading brands
including approval history, sales and market position, SWOT analysis, and
strategy initiatives.
- Physician Perception of Key Brands: Analysis of physician
perceptions of the UA/NSTEMI market based on a custom survey of 50 U.S.
cardiologists and interventional cardiologists. The survey is brand-focused
and examines physician perceptions of key competitors, brand attributes, and
uptake of emerging agents.
- Epidemiology: Total prevalent and diagnosed cases for each of the
major markets are presented in an annualized forecast from 2006 to 2011.
- Market Forecast: Annualized sales forecasts for branded agents
presented by region, drug class, molecule, and brand for 2006 to 2011,
including the uptake of new agents.
|
Related Report
|
View Cart
